In infant ALL, KMT2A gene rearrangements are linked to poor prognosis, particularly in infants diagnosed before the age of 6 months, present with a WBC count of at least 300 × 109/L, or have a poor response to induction therapy with steroids [85]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.